Income Taxes - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Valuation allowance related to acquisition	$ 59,598	$ 70,529	$ 582	$ 11
Deferred tax assets, tax deferred expense	9,100
Research and development credit carryforwards	0	1,600
Net tax benefit as a result of statutes of limitation	1,700	100	600
Tax expense on uncertain tax positions	30	300	$ 300
Tax expense related to prior year position	40
Adamas Pharmaceuticals
Operating Loss Carryforwards [Line Items]
Valuation allowance related to acquisition		$ 69,700
Deferred tax assets, tax deferred expense	8,900
U.S. Federal
Operating Loss Carryforwards [Line Items]
NOL carryforwards	416,700
NOLs utilized	34,800
U.S. Federal | Adamas Pharmaceuticals
Operating Loss Carryforwards [Line Items]
NOL carryforwards	488,400
State
Operating Loss Carryforwards [Line Items]
NOLs utilized	$ 24,800